Last reviewed · How we verify
NCT03960333: IPO
Immunometabolism in Pediatric Obesity
trial in Obesity in 82 participants. Completed in 30 June 2024.
5 February 2021
Quick facts
| Lead sponsor | Arkansas Children's Hospital Research Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 82 |
| Start date | 25 April 2019 |
| Primary completion | 5 February 2021 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across United States |
Conditions studied
- Obesity — all drugs for Obesity →
- Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
- Insulin Resistance — all drugs for Insulin Resistance →
Sponsor
Arkansas Children's Hospital Research Institute
Who can join
Adults 5 to 17, any sex, with Obesity or Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study to learn about obesity and how insulin resistance and Type 2 Diabetes develops in children.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Metabolic regulation of the immune system in health and diseases: mechanisms and interventions.
Hu T, Liu CH, Lei M, Zeng Q, et al · · 2024 · cited 135× · PMID 39379377 · DOI 10.1038/s41392-024-01954-6 -
Regulatory T cells and bioenergetics of peripheral blood mononuclear cells linked to pediatric obesity.
Rose S, Landes RD, Vyas KK, Delhey L, et al · · 2024 · cited 4× · PMID 38680993 · DOI 10.1097/in9.0000000000000040
Verify or expand the search:
- PubMed search for NCT03960333
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Arkansas Children's Hospital Research Institute trials
Trials by the same sponsor.
- NCT06929091 — Effect of Prenatal and Postnatal Intervention Strategies on Breastfeeding Outcomes in Women With Excessive Weight (Ready · NA · recruiting
- NCT06848478 — Level Up! (The Combined and Independent Effects of Exercise Training and Dietary Enhancement on Cardiometabolic Health i · NA · not yet recruiting
- NCT06666257 — Continuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancies - The GEM Study · NA · not yet recruiting
- NCT07107321 — Deimplementation of Inappropriate Feeding Practices in Early Care and Education Settings · NA · enrolling by invitation
- NCT07346300 — We-Move With Windy: Gross Motor Development for Early Childhood · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03960333 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Arkansas Children's Hospital Research Institute
- Last refreshed: 13 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03960333.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing